Cargando…
Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis
PURPOSE: To evaluate 10 years of KAMRA corneal inlay explantation and associated visual outcomes. PATIENTS AND METHODS: Single-site retrospective chart review of 22 cases of AcuFocus KAMRA Inlay (ACI7000PDT) explantation (range 1 week–1 year). Uncorrected distance visual acuity (UDVA), uncorrected n...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553435/ https://www.ncbi.nlm.nih.gov/pubmed/36237487 http://dx.doi.org/10.2147/OPTH.S382544 |
_version_ | 1784806470097829888 |
---|---|
author | Moshirfar, Majid Lau, Chap-Kay Chartrand, Nicholas A Parsons, Mark T Stapley, Seth Bundogji, Nour Ronquillo, Yasmyne C Linn, Steven H Hoopes, Phillip C |
author_facet | Moshirfar, Majid Lau, Chap-Kay Chartrand, Nicholas A Parsons, Mark T Stapley, Seth Bundogji, Nour Ronquillo, Yasmyne C Linn, Steven H Hoopes, Phillip C |
author_sort | Moshirfar, Majid |
collection | PubMed |
description | PURPOSE: To evaluate 10 years of KAMRA corneal inlay explantation and associated visual outcomes. PATIENTS AND METHODS: Single-site retrospective chart review of 22 cases of AcuFocus KAMRA Inlay (ACI7000PDT) explantation (range 1 week–1 year). Uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), corrected distance visual acuity (CDVA), and manifest refraction at 1 day, 1 week, 1 month, 3 months, 6 months, and 1 year post-explantation were reviewed. RESULTS: The explantation rate was 8.2% across 10 years. All patients underwent KAMRA explantation due to dissatisfaction with their vision including blurry near vision, impaired night vision, decreased vision in dim lighting, streaks or halos, haze, and double vision. Mean UDVA pre-implant was −0.01±0.13 logMAR (logarithm of the minimal angle of resolution), 0.30±0.22 logMAR pre-explant, and 0.16±0.15 logMAR post-explant (n=20). Mean UNVA pre-implant was 0.37±0.09 logMAR, 0.38±0.13 logMAR pre-explant, and 0.42±0.21 logMAR post-explant (n=20). Mean CDVA pre-implant was −0.01±0.04 logMAR and 0.05±0.11 logMAR post-explant (n=17). Mean CDVA pre-explant was 0.04±0.07 logMAR and 0.04±0.11 logMAR post-explant (n=19). Significant differences were observed between pre-implant and post-explant UDVA (p=0.009), and between pre-explant and post-explant UDVA (p=0.02). All patients (100%) had 20/20 or better CDVA pre-implant but decreased to 73.7% post-explant. Sixty percent (12/20) of the patients lost UDVA Snellen acuity lines post-explant. MRSE was −0.31±0.29 D pre-implant and +0.26±0.77 D post-explant (p=0.007) with note of a hyperopic shift. The hyperopic shift in 31.6% (6/19) of patients did not resolve after explantation. Post-explant residual corneal haze occurred in 72.7% (16/22) of patients. CONCLUSION: Although the KAMRA corneal inlay is a removable device, patients may experience residual corneal haze, hyperopic shift, and deficits in UDVA after explantation compared to pre-implantation UDVA. |
format | Online Article Text |
id | pubmed-9553435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-95534352022-10-12 Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis Moshirfar, Majid Lau, Chap-Kay Chartrand, Nicholas A Parsons, Mark T Stapley, Seth Bundogji, Nour Ronquillo, Yasmyne C Linn, Steven H Hoopes, Phillip C Clin Ophthalmol Original Research PURPOSE: To evaluate 10 years of KAMRA corneal inlay explantation and associated visual outcomes. PATIENTS AND METHODS: Single-site retrospective chart review of 22 cases of AcuFocus KAMRA Inlay (ACI7000PDT) explantation (range 1 week–1 year). Uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), corrected distance visual acuity (CDVA), and manifest refraction at 1 day, 1 week, 1 month, 3 months, 6 months, and 1 year post-explantation were reviewed. RESULTS: The explantation rate was 8.2% across 10 years. All patients underwent KAMRA explantation due to dissatisfaction with their vision including blurry near vision, impaired night vision, decreased vision in dim lighting, streaks or halos, haze, and double vision. Mean UDVA pre-implant was −0.01±0.13 logMAR (logarithm of the minimal angle of resolution), 0.30±0.22 logMAR pre-explant, and 0.16±0.15 logMAR post-explant (n=20). Mean UNVA pre-implant was 0.37±0.09 logMAR, 0.38±0.13 logMAR pre-explant, and 0.42±0.21 logMAR post-explant (n=20). Mean CDVA pre-implant was −0.01±0.04 logMAR and 0.05±0.11 logMAR post-explant (n=17). Mean CDVA pre-explant was 0.04±0.07 logMAR and 0.04±0.11 logMAR post-explant (n=19). Significant differences were observed between pre-implant and post-explant UDVA (p=0.009), and between pre-explant and post-explant UDVA (p=0.02). All patients (100%) had 20/20 or better CDVA pre-implant but decreased to 73.7% post-explant. Sixty percent (12/20) of the patients lost UDVA Snellen acuity lines post-explant. MRSE was −0.31±0.29 D pre-implant and +0.26±0.77 D post-explant (p=0.007) with note of a hyperopic shift. The hyperopic shift in 31.6% (6/19) of patients did not resolve after explantation. Post-explant residual corneal haze occurred in 72.7% (16/22) of patients. CONCLUSION: Although the KAMRA corneal inlay is a removable device, patients may experience residual corneal haze, hyperopic shift, and deficits in UDVA after explantation compared to pre-implantation UDVA. Dove 2022-10-10 /pmc/articles/PMC9553435/ /pubmed/36237487 http://dx.doi.org/10.2147/OPTH.S382544 Text en © 2022 Moshirfar et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Moshirfar, Majid Lau, Chap-Kay Chartrand, Nicholas A Parsons, Mark T Stapley, Seth Bundogji, Nour Ronquillo, Yasmyne C Linn, Steven H Hoopes, Phillip C Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title | Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title_full | Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title_fullStr | Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title_full_unstemmed | Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title_short | Explantation of KAMRA Corneal Inlay: 10-Year Occurrence and Visual Outcome Analysis |
title_sort | explantation of kamra corneal inlay: 10-year occurrence and visual outcome analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553435/ https://www.ncbi.nlm.nih.gov/pubmed/36237487 http://dx.doi.org/10.2147/OPTH.S382544 |
work_keys_str_mv | AT moshirfarmajid explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT lauchapkay explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT chartrandnicholasa explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT parsonsmarkt explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT stapleyseth explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT bundogjinour explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT ronquilloyasmynec explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT linnstevenh explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis AT hoopesphillipc explantationofkamracornealinlay10yearoccurrenceandvisualoutcomeanalysis |